Researchers have identified a link between Wegovy, a popular GLP-1 weight-loss drug, and retinal artery occlusion, a rare condition that causes sudden vision loss. The condition occurs when blood flow to the retina stops abruptly.
Early data shows the risk appears higher with Wegovy than with other GLP-1 drugs in the same class, though cases remain uncommon overall. The mechanism behind the link remains unclear. Scientists have proposed several theories, including the possibility that rapid weight loss stresses the cardiovascular system or that GLP-1 drugs affect blood vessel function.
The FDA has not issued a warning about this risk. Health officials are monitoring the situation as more cases accumulate in medical records. Doctors treating patients on Wegovy should watch for sudden vision changes, eye pain, or vision loss, particularly in patients with existing cardiovascular risk factors.
This discovery highlights a broader pattern with GLP-1 drugs. As millions of people use these medications for weight loss and diabetes management, uncommon side effects emerge. Patients considering Wegovy should discuss individual risk factors with their doctors. The benefits of weight loss often outweigh rare risks for many people, but informed decision-making requires knowledge of these emerging concerns.